Lipid metabolism has emerged as a central player in the progression and therapy resistance of breast cancer, particularly the aggressive subtype known as triple-negative breast cancer (TNBC).

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual ...